BioMarin Pharmaceutical has posted a Q4 loss of $12.2m, despite a 17% increase in revenue to $101.6m, and forecasted further losses in 2011.
The company had reported a profit of $4.7m during the same period a year earlier.
Operating expenses rose 30% to $105m, accredited to increased research and development costs while the company witnessed a $13.7m charge due to early conversion of convertible debt.
Sales of Naglazyme, Andurazyme and Kuvan rose 2%, 9.8% and 20% respectively, attributing to increased revenue for the full year of $376.3m.
For 2011, the company expects revenue of up to $452m resulting in a net loss of between $48m and $60m.